A 2 minute assessment to get a personalized mental health or alcohol recovery plan.
Two FDA-approved medications. Two different mechanisms. One may fit your life far better than the other.
What You'll Discover:
• How naltrexone and acamprosate each work in the brain
• The key differences in who each medication is designed for
• Why your personal goal (reduce or quit) matters when choosing
• What the landmark COMBINE trial found about both drugs
• How to take a next step toward evidence-based alcohol care
Choosing between two FDA-approved medications for alcohol use disorder is a real and reasonable decision to face. Both naltrexone and acamprosate have decades of research behind them.
They work differently, require different starting conditions, and fit different goals. Knowing the distinction changes the conversation you have with your doctor.
What Is Alcohol Use Disorder?
Alcohol Use Disorder (AUD) is a medical diagnosis, not a moral failing. It describes a pattern of drinking that causes distress or interferes with daily life, on a spectrum from mild to severe.
The National Institute on Alcohol Abuse and Alcoholism recognizes AUD as a medical condition affecting millions of Americans. Most people who have it never receive any treatment at all.
The good news: it is treatable. FDA-approved medications, combined with behavioral support, give most people a meaningful and measurable advantage.
You do not need to have reached a crisis point to pursue treatment. People at every stage of AUD, from mild to severe, benefit from the medications covered here.
How Naltrexone Works
Naltrexone is an opioid antagonist. It blocks the mu-opioid receptors in your brain that alcohol activates.
When you drink while on naltrexone, the brain does not release the usual flood of dopamine-linked reward signals. The buzz is reduced. The craving that follows that first drink fades.
Over time, the association between drinking and pleasure weakens at a neurological level. Naltrexone is not willpower in a pill. It is a mechanism change: the brain stops being rewarded for drinking.
As outlined in the StatPearls naltrexone entry at NCBI, naltrexone is typically dosed at 50 mg once daily. It reaches peak concentration within about an hour, which is why you take it before drinking when using it as needed.
Some patients start at 25 mg to minimize early side effects, then move up to the standard 50 mg dose. Others may take a higher dose. Your prescribing physician sets the right amount based on your health history and goals.
The medication has a half-life of about four hours, but it remains active and effective in your system for 20 to 24 hours after a single dose. That means taking it once each morning keeps it working all day.
For a deeper look at the mechanism, our guide on how naltrexone works walks through the science step by step.
Key practical fact: You do not need to be abstinent to start naltrexone. Many patients begin while still drinking, and that is by design.
This approach is known as the Sinclair Method. You take the medication before drinking to gradually retrain the brain's reward response over weeks and months.
How Acamprosate Works
Acamprosate works through a completely different mechanism. It does not block opioid receptors and does not affect the reward pathway the way naltrexone does.
Instead, it helps stabilize the glutamate and GABA neurotransmitter systems. These systems become dysregulated when someone stops drinking after heavy or prolonged alcohol use.
The balance between excitatory signaling (glutamate) and inhibitory signaling (GABA) gets thrown off by years of heavy drinking. When alcohol is suddenly removed, the brain is left in a hyper-excitable state.
That dysregulation produces anxiety, restlessness, irritability, and a persistent sense of unease in early sobriety. It is a real physiological state, not just a mood. Acamprosate targets that state.
It does not reduce active cravings for alcohol in a real-time sense. It does not blunt the reward of a drink in the moment. Its job is to make the neurological experience of being sober more comfortable for someone who has already stopped drinking.
Think of it this way: naltrexone changes how drinking feels. Acamprosate changes how not drinking feels.
Acamprosate is most beneficial for people who have completed detox but still struggle with the discomfort of early sobriety.
It takes several days to reach a therapeutic level in the body, so it is started immediately after detox and taken consistently to work.
The Single Most Important Practical Difference
This is the distinction that matters most for most people reading this.
Acamprosate requires prior abstinence. It is only effective after detox. You must have stopped drinking before starting it. The drug is not approved or designed for people who are actively drinking.
Naltrexone does not require abstinence. You can start it while still drinking. This makes it viable for people who are not yet ready to commit to complete sobriety from day one.
That is the situation most people find themselves in when they first reach out for help.
For anyone exploring a harm reduction approach to alcohol, meaning reducing consumption rather than quitting entirely, naltrexone is the only one of the two that directly supports that path.
Acamprosate simply cannot be used by someone who is still drinking. That is not a knock on the medication. It is a structural fact that should drive the conversation about which drug makes sense for where you are right now.
Side-by-Side Comparison
Goal Fit
Naltrexone is effective for both abstinence goals and controlled drinking goals. It works whether your aim is to quit completely or simply drink far less than you currently do.
Acamprosate is designed exclusively for maintaining abstinence after you have already stopped. It does not help people who want to drink less but not quit.
Dosing and Adherence
Naltrexone is one tablet (50 mg) taken once per day. That is straightforward, and most people find once-daily dosing easy to build into a routine.
Acamprosate is two 333 mg tablets taken three times per day, totaling six tablets daily. Adherence can be a real challenge with a three-times-daily regimen, and missed doses reduce effectiveness.
When You Can Start
Naltrexone: you can begin while still drinking. No waiting period after your last drink, though a clinician will confirm you are not using opioids first.
Acamprosate: you must be abstinent first. It is typically started after completing a medically supervised detox, or after reaching a stable period of sobriety on your own.
Kidney and Liver Considerations
Naltrexone is processed by the liver. It should be used with caution in people with significant liver disease, though research confirms naltrexone is safe at therapeutic doses for most patients.
At the standard 50 mg dose, liver toxicity is not a practical concern for the vast majority of people seeking AUD treatment.
Acamprosate is processed primarily by the kidneys, not the liver. It is often the preferred option for patients who have liver concerns but intact kidney function. The tradeoff is that it cannot be used in people with significant kidney disease.
Common Side Effects
Naltrexone: nausea is the most frequently reported side effect, usually mild and improving within the first week or two. Headache and fatigue are also possible, particularly in the first few days.
Acamprosate: the most common side effects are diarrhea, nausea, and general gastrointestinal discomfort. These tend to be manageable and often improve over time.
Both medications are well tolerated by most patients. Neither is sedating or habit-forming, and neither produces euphoria.
What the Clinical Evidence Shows
The COMBINE Trial
The COMBINE study, published in JAMA, is one of the largest clinical trials ever conducted on AUD medications. It enrolled over 1,383 patients at 11 U.S. sites and tested naltrexone, acamprosate, and behavioral therapy in various combinations over 16 weeks.
The findings at PubMed were striking. Naltrexone significantly reduced the risk of a heavy drinking day, producing a hazard ratio of 0.72 compared to placebo.
Acamprosate showed no significant benefit over placebo in the COMBINE trial, either alone or in combination with other treatments. That result surprised many researchers, because acamprosate had shown effectiveness in European studies.
The likely explanation: the COMBINE trial enrolled participants who had not completed a full medically supervised detox. Acamprosate is specifically designed for people who have already cleared that hurdle.
European trials of acamprosate typically required inpatient detox before enrollment. The COMBINE trial did not. That methodological difference may explain nearly all of acamprosate's apparent underperformance in U.S. research.
The 2023 JAMA Meta-Analysis
A large 2023 meta-analysis covered 118 clinical trials and over 20,000 patients, providing the clearest head-to-head picture available.
Oral naltrexone at 50 mg had a Number Needed to Treat (NNT) of 11 to prevent one additional person from returning to heavy drinking compared to placebo.
Acamprosate showed an NNT of 11 for preventing any return to drinking in studies focused on post-detox abstinence maintenance.
Both numbers represent real clinical benefit. An NNT of 11 means that for every 11 people who take the medication, one additional person achieves the target outcome compared to placebo.
To put that in context: most commonly used medications in medicine have NNTs ranging from 5 to 20. An NNT of 11 is clinically meaningful. It is not a cure, but it is a real and measurable edge.
The honest interpretation: both medications have genuine clinical support. Naltrexone's evidence base spans both abstinence and harm-reduction contexts, and it showed effectiveness across the full range of COMBINE patients.
Acamprosate's evidence is largely limited to post-detox abstinence maintenance, in people who have already completed a full medical detox before starting.
Who Is Each Medication Best For?
Naltrexone is likely the better fit if you want to reduce how much you drink without necessarily quitting entirely. It is also the stronger choice if you are not yet ready to complete a formal detox before starting treatment.
It is the better option if you prefer a once-daily pill, if you are curious about the Sinclair Method, or if you have a functioning liver and are not using any opioid medications.
Most people who contact an alcohol care program are still drinking and have not completed detox. Naltrexone is designed for that starting point.
Acamprosate may be worth discussing with your doctor if you have already completed detox and are fully abstinent.
It may also make more sense if you have liver disease that makes naltrexone a concern but have normal kidney function, and if complete abstinence is your only goal.
All that said, neither medication is universally superior. A prescribing clinician can help you weigh the tradeoffs based on your health history, your goals, and your current situation.
There is no shame in asking about both options during a clinical conversation. The more clearly you can describe where you are right now, the better your provider can match the medication to your situation.
Can You Take Both at the Same Time?
Some clinicians have prescribed both medications together, particularly for patients who want both post-detox neurochemical stabilization and ongoing craving reduction.
The combination is generally considered safe. The two drugs work through entirely different mechanisms and do not interact with each other.
However, the COMBINE study found no added benefit from combining the two over using naltrexone alone with medical management. For most patients, starting with one well-chosen medication is a more practical and evidence-supported approach.
If you start with naltrexone and achieve meaningful reduction or abstinence, there is typically no reason to add acamprosate. The combination makes the most sense in specific clinical scenarios, which is a conversation to have directly with a prescribing doctor.
A Note on the Sinclair Method
The Sinclair Method uses naltrexone specifically as a tool for extinction-based learning. You take the medication one to two hours before drinking, every time you drink, rather than on a fixed daily schedule.
This allows the brain to experience drinking without the reward response, again and again. Over weeks and months, the conditioned craving gradually weakens.
For many people, drinking loses its appeal without them needing to white-knuckle their way through anything. The treatment works by removing the reinforcement, not by demanding willpower.
Our article on the Sinclair Method explains the full protocol and what the research shows.
This approach is only possible with naltrexone. Acamprosate has no equivalent use pattern because it does not interact with the reward system that drives drinking behavior.
How to Know Which One to Ask Your Doctor About
A few practical factors can help clarify the conversation with your doctor.
Consider where you are starting from: whether you have completed detox, whether your goal is to quit completely or simply drink far less, whether you have liver or kidney disease, and whether you are currently using any opioid medications.
If you are still actively drinking, have not completed detox, or your goal is reduction rather than abstinence, naltrexone is almost certainly the right first conversation.
It is accessible, flexible, and effective across a wider range of starting points than any other FDA-approved AUD medication.
If you are already sober after detox, committed to full abstinence, and have liver concerns, acamprosate may be worth exploring with your provider. The key word is "after." Acamprosate is a post-detox tool, not a starting-point tool.
A good primary care doctor or addiction medicine physician can help you think through both options. Many people work with a telehealth provider because it is more accessible and less stigmatizing than an in-person clinic visit.
For a broader overview of how these medications fit into the full treatment landscape, our guide to medications for alcohol use disorder covers additional context.
Cost and Access
Cost is a practical part of any treatment decision. Both naltrexone and acamprosate require a prescription, but the access picture is different for each.
Generic naltrexone (50 mg tablets) is widely available and relatively affordable. Cash prices at major pharmacies typically run $40 to $80 per month without insurance, and many insurance plans cover it.
Acamprosate (generic: calcium acamprosate) is also available as a generic, typically costing $100 to $200 per month without insurance. The three-times-daily regimen means a higher monthly pill count, which contributes to the higher cost.
Telehealth platforms that prescribe naltrexone have made access significantly easier for many people. You can start the assessment process from home, without visiting a clinic in person.
Acamprosate has no comparable telehealth pathway because it requires prior detox verification. It is typically prescribed through an in-person physician or through addiction specialists following a formal detox program.
Safety, Supervision, and Starting Treatment
Neither naltrexone nor acamprosate should be started without a clinician's involvement.
Naltrexone requires a prescription and an intake process that screens for opioid use. Taking naltrexone while opioids are in your system can trigger acute withdrawal, which can be severe.
A prescribing physician will always confirm opioid status before approving naltrexone.
Acamprosate also requires a prescription. Your doctor will confirm you have completed detox and will assess kidney function before prescribing.
In people with significant kidney impairment, acamprosate requires dose adjustment or may not be appropriate.
Both medications are most effective when combined with behavioral support, whether that is coaching, counseling, group support, or some combination of all three.
Medication is a meaningful tool. It works better when paired with accountability and guidance.
Talk with your doctor if side effects seem severe, if the medication is not working after several weeks, or if your drinking patterns change significantly.
Dosage can be adjusted, and the treatment approach can be refined based on how you respond.
Conclusion
Naltrexone and acamprosate are both legitimate, FDA-approved options for alcohol use disorder. They just solve different problems.
Acamprosate helps people maintain abstinence after detox by smoothing out the neurochemical disruption of early sobriety. It is a post-detox maintenance tool, and it works best for people who have already cleared that hurdle.
Naltrexone works by removing the reward of drinking. It can be started before abstinence, used for harm reduction, and taken once daily.
The evidence base for naltrexone is broader. It applies to more people at more stages of their relationship with alcohol.
And unlike acamprosate, it can meet you wherever you are. You do not need to have checked into a detox facility first. You do not need to have your last drink already behind you.
For most people who are not yet fully abstinent, who want flexibility in their goals, or who want to start treatment without a formal detox first, naltrexone is the more accessible and better-supported starting point.
The most important step is talking to a clinician who takes your situation seriously. You do not need to have hit rock bottom. You do not need a label. You just need honest information and a plan that fits your life.
If you are ready to explore whether naltrexone could work for you, take a quick, discreet online Alcohol Use Assessment to see if Choose Your Horizon's naltrexone program makes sense for your situation.
